Non-Stimulant ADHD Medications for ADHD
Effective ADHD treatment without controlled substances — for patients who prefer to avoid stimulants
Overview
Non-stimulant medications are an important option for patients who cannot tolerate stimulants, have a history of substance use disorder, have cardiovascular contraindications, or simply prefer to avoid Schedule II controlled substances. While non-stimulants generally have slower onset and may be less dramatically effective than stimulants, they provide meaningful symptom relief for many patients.
How It Works
Each non-stimulant works differently: Atomoxetine (Strattera) selectively inhibits norepinephrine reuptake. Bupropion (Wellbutrin) inhibits dopamine and norepinephrine reuptake. Guanfacine (Intuniv) and clonidine (Kapvay) are alpha-2 adrenergic agonists that strengthen prefrontal cortex function through a distinct mechanism.
Available Formulations
- Atomoxetine (Strattera) — once or twice daily, generic available
- Bupropion XL (Wellbutrin) — once daily, also treats depression and helps with smoking cessation
- Guanfacine ER (Intuniv) — once daily, also reduces blood pressure
- Clonidine ER (Kapvay) — twice daily, useful for ADHD with significant hyperactivity
- Viloxazine ER (Qelbree) — newest non-stimulant, similar to atomoxetine
Side Effects & Monitoring
- ⚠ Atomoxetine: nausea (take with food), decreased appetite, mood changes, rare liver toxicity (monitor)
- ⚠ Bupropion: insomnia, decreased appetite, headache, seizure risk in eating disorders
- ⚠ Guanfacine/Clonidine: sedation (particularly initially), low blood pressure, rebound hypertension if stopped abruptly
- ⚠ All non-stimulants: 4–6 week onset to full therapeutic effect (unlike stimulants, which work immediately)
Monitoring: Atomoxetine: liver function tests if symptoms develop. Guanfacine/Clonidine: blood pressure monitoring, particularly when adjusting doses. Bupropion: mood monitoring, particularly in patients with bipolar disorder (can trigger mania). All: symptom response assessment at 4–6 weeks after reaching target dose.
Prescription Management With Direct Access
ADHD medication often requires adjustment in the first months of treatment — dose titration, formulation changes, timing adjustments. With Dr. Agresti's concierge model, you can text him directly when something isn't working. No 6-week wait for the next appointment to report that your medication stops working by 2 PM.
Schedule an ADHD EvaluationFrequently Asked Questions
Stimulants have larger average effect sizes, but non-stimulants like atomoxetine (Strattera), guanfacine (Intuniv), and bupropion (Wellbutrin) produce excellent results for many patients — especially those with anxiety, tics, cardiac concerns, or a history of substance use. The right question is which medication fits you, not which wins on averages.
Patients with significant anxiety, a personal or family history of addiction, cardiovascular risk factors, sleep problems worsened by stimulants, or those who simply did not tolerate stimulant side effects. Non-stimulants are also not controlled substances, which simplifies refills and travel.
Unlike stimulants, atomoxetine builds gradually — most patients notice benefits at 2–4 weeks with full effect around 6–8 weeks. Dr. Agresti sets expectations up front and adjusts the dose along the way so patients do not abandon an effective medication too early.
Yes, in selected cases. A common strategy pairs a low-dose stimulant with guanfacine to smooth evening symptoms and rebound. This kind of combination management is exactly what a psychopharmacology-focused practice is for.